Structure-activity relationships of [2′,5′-bis-O-(tert- butyldimethylsilyl)-β-D-ribofuranosyl]-3′-spiro-5″-(4″- amino-1″,2″-oxathiole-2″,2″-dioxide)thymine derivatives as inhibitors of HIV-1 reverse transcriptase dimerization

Journal of Medicinal Chemistry

Volumn 49, Issue 16, 2006, Pages 4834-4841

  Sluis Cremer, Nicolas ^a   Hamamouch, Noureddine ^a   San Félix, Ana ^b   Velázquez, Sonsoles ^b   Balzarini, Jan ^c   Camarasa, María José ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

[2',5' BIS O (TERT BUTYLDIMETHYLSILYL) BETA DEXTRO RIBOFURANOSYL] 3' SPIRO 5'' (4'' AMINO 1'',2'' OXATHIOLE 2'',2'' DIOXIDE)THYMINE DERIVATIVE; DNA POLYMERASE; EFAVIRENZ; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; CYTOSTASIS; CYTOTOXICITY; DIMERIZATION; DRUG DESIGN; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; MOLECULAR CLONING; PROTEIN PURIFICATION; STATISTICAL ANALYSIS; STRUCTURE ACTIVITY RELATION; TWO HYBRID SYSTEM;

ANTI-HIV AGENTS; CELL LINE; COMBINATORIAL CHEMISTRY TECHNIQUES; DIMERIZATION; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS; SPIRO COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP; THYMIDINE;

EID: 33746948397     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0604575     Document Type: Article

References (50)

1. Miller, M. D.; Hazuda, D. J. New antiretroviral agents: looking beyond protease and reverse transcriptase. Curr. Opin. Microbiol. 2001, 4, 535-539.
2. Condra, J. H.; Miller, M. D.; Hazuda, D. J.; Emini, E. A. Potential new therapies for the treatment of HIV-1 infection. Annu. Rev. Med. 2002, 53, 541-555.
3. Telesnitsky, A.; Goff, S. In Reverse Transcriptase and the Generation of Retroviral DNA in Retroviruses; Coffin, J., Hughes, S., Varmus, H., Eds.; Cold Spring Harbor Laboratory Press: Plainview, NY, 1997; pp 121-160.
4. Kohlsteaedt, L. A.; Wang, J.; Friedman, J. M.; Rice, P. A.; Steitz, T. A. Crystal structure of 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992, 256, 1783-1790.
5. Wang, J.; Smerdon, S. J.; Jager, J.; Kohlstaedt, L. A.; Rice, P. A.; Friedman, J. M.; Steitz, T. A. Structural basis of asymmetry in the human immunodeficiency virus type 1 reverse transcriptase heterodimer. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 7242-7246.
6. di Marzo Veronese, F.; Copeland, T. D.; DeVico, A. L.; Rahman, R.; Oroszlan, S.; Gallo, R. C.; Sarngadharan, M. G. Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV. Science 1986, 231, 1289-1291.
7. Restle, T.; Müller, B.; Goody, R. S. Dimerization of human immunodeficiency virus type 1 reverse transcriptase: A target for chemotherapeutic intervention. J. Biol. Chem. 1990, 265, 8986-8988.
8. Tachedjian, G.; Radzio, J.; Sluis-Cremer, N. Relationship between enzyme activity and dimeric structure of recombinant HIV-1 reverse transcriptase. Proteins 2005, 60, 5-13.
9. Divita, G.; Restle, T.; Goody, R. S.; Chermann, J. C.; Baillon, J. G. Inhibition of human immunodeficiency virus type 1 reverse transcriptase dimerization using synthetic peptides derived from the connection domain. J. Biol. Chem. 1994, 269, 13080-13083.
10. Divita, G.; Baillon, J. G.; Rittinger, K.; Chermann, J. C.; Goody, R. S. Interface peptides as structure-based human immunodeficiency virus reverse transcriptase inhibitors. J. Biol. Chem. 1995, 270, 28642-28646.
11. Morris, M. C.; Robert-Hebmann, V.; Chaloin, L.; Mery, J.; Heitz, F.; Devaux, C.; Goody, R. S.; Divita, G. A new potent HIV-1 reverse transcriptase inhibitor. A synthetic peptide derived from the interface subunit domains. J. Biol. Chem. 1999, 274, 24941-24946.
12. Morris, M. C.; Berducou, C.; Mery, J.; Heitz, F.; Divita, G. The thumb domain of the p51-subunit is essential for activation of HIV reverse transcriptase. Biochemistry 1999, 38, 15097-15103.
13. Sluis-Cremer, N.; Dmitrienko, G. I.; Balzarini, J.; Camarasa, M. J.; Parniak, M. A. Human immunodeficiency virus type 1 reverse transcriptase dimer destabilization by 1-[Spiro[4″-amino-2″,2″-dioxo-1″, 2″-oxathiole-5″,3′-[2′,5′-bis-O-(tert- butyldimethylsilyl)-βD-ribofuranosyl]]]-3-ethylthymine. Biochemistry 2000, 39, 1427-1433.
14. Sluis-Cremer, N.; Arion, D.; Parniak, M. A. Destabilization of the HIV-1 reverse transcriptase dimer upon interaction with N-acyl hydrazone inhibitors. Mol. Pharmacol. 2002, 62, 398-405.
15. Sluis-Cremer, N.; Tachedjian, G. Modulation of the oligomeric structures of HIV-1 retroviral enzymes by synthetic peptides and small molecules. Eur. J. Biochem. 2002, 269, 5103-5111.
16. Camarasa, M. J.; San-Félix, A.; Velázquez, S.; Pérez-Pérez, M. J.; Gago, F.; Balzarini, J. TSAO compounds: the comprehensive story of a unique family of HIV-1 specific inhibitors of reverse transcriptase. Curr. Top. Med. Chem. 2004, 4, 945-963.
17. Rodríguez-Barrios, F.; Perez, C.; Lobatón, E.; Velázquez, S.; Chamorro, C.; San-Feŕlix, A.; Pérez- Pérez, M. J.; Camarasa, M. J.; Pelemans, H.; Balzarini, J.; Gago, F. Identification of a putative binding site for [2′,5′-bis-O-(tert- butyldimethylsilyl)-β-D-ribofuranosyl]-3′-spiro-5″-(4″- amino-1″,2″-oxathiole-2″,2″-dioxide)thymine (TSAO) derivatives at the p51-p66 interface of HIV-1 reverse transcriptase. J. Med. Chem. 2001, 44, 1853-1865.
18. Balzarini, J.; Karlsson, A.; Vandamme, A. M.; Pérez-Pérez, M. J.; Zhang, H.; Vrang, Ll. Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1 specific [2′,5′-bis-O- (tert-butyldimethylsilyl)-3′-spiro-5″-(4″-amino-1″, 2″-oxathiole-2″,2″-dioxide)]-β-D-pentofuranosyl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific nonnucleoside inhibitors. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 6952-6956.
19. 138→Lys on the p51 subunit. J. Biol. Chem. 1994, 269, 25255-25258.
20. Lebowitz, J.; Kar, S.; Braswell, E.; McPherson, S.; Richard, D. L. Human immunodeficiency virus-1 reverse transcriptase heterodimer stability. Protein Sci. 1994, 3, 1374-1382.
21. Divita, G.; Rittinger, K.; Geourjon, C.; Deleage, G.; Goody, R. S. Dimerization kinetics of HIV-1 and HIV-2 reverse transcriptase: a two step process. J. Mol. Biol. 1995, 245, 508-521.
22. Divita, G.; Restle, T.; Goody, R. S. Characterization of the dimerization process of HIV-1 reverse transcriptase heterodimer using intrinsic protein fluorescence. FEBS Lett. 1993, 324, 153-158.
23. Debyser, Z.; De Clercq, E. Chemical cross-linking of the subunits of HIV-1 reverse transcriptase. Protein Sci. 1996, 5, 278-286.
24. Tachedjian, G.; Aronson, H. E.; Goff, S. P. Analysis of mutations and suppressors affecting interactions between the subunits of the HIV type 1 reverse transcriptase. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 6334-6339.
25. Zhang, J. H.; Chung, T. D.; Oldenburgh, K. R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screening 1999, 4, 27-32.
26. Macarrón, R.; Hertzberg, R. P. Design and Implementation of High Throughput Screening Assays. In Methods in Molecular Biology; Janzen, W. P., Ed.; Humana Press: Totowa, NJ, 2002; Vol. 190, pp 1-29.
27. Tachedjian, G.; Orlova, M.; Sarafianos, S. G.; Arnold, E.; Goff, S. P. Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 7188-7193.
28. Tachedjian, G.; Moore, K. L.; Goff, S. P.; Sluis-Cremer, N. Efavirenz enhances the proteolytic processing of an HIV-1 pol polyprotein precursor and reverse transcriptase homodimer formation. FEBS Lett. 2005, 579, 379-384.
29. Chamorro, C.; Lobatón, E.; Bonache, M. C.; De Clercq, E.; Balzarini, J.; Velázquez, S.; Camarasa, M. J.; San-Félix, A. Identification of a novel family of nucleosides that specifically inhibit HIV-1 reverse transcriptase. Bioorg. Med. Chem. Lett. 2001, 11, 3085-3088.
30. Bonache, M. C.; Chamorro, C.; Lobatón, E.; De Clercq, E.; Balzarini, J.; Velázquez, S.; Camarasa, M. J.; San-Félix, A. Structure-activity relationship studies on a novel family of specific HIV-1 reverse transcriptase inhibitors. Antiviral Chem. Chemother. 2003, 14, 249-262.
31. Bonache, M. C.; Chamorro, C.; Velázquez, S.; De Clercq, E.; Balzarini, J.; Barrios, F. R.; Gago, F.; Camarasa, M. J.; San-Félix, A. Improving the antiviral efficacy and selectivity of HIV-1 reverse transcriptase inhibitor TSAO-T by the introduction of functional groups at the N-3 position. J. Med. Chem. 2005, 48, 6653-6660.
32. Camarasa, M. J.; Pérez-Pérez, M. J.; San-Félix, A.; Balzarini, J.; De Clercq, E. 3′-Spiro nucleosides, a new class of specific human immunodeficiency virus type 1 inhibitors: synthesis and antiviral activity of [2′-5′-bis-O-(tert-butyldimethylsilyl)-β-D-xylo- and -ribofuranose]-3′-spiro-5″-[4″-amino-1 ″,2″-oxathiole 2″,2″-dioxide] (TSAO) pyrimidine nucleosides. J. Med. Chem. 1992, 35, 2721-2727.
33. Pérez-Pérez, M. J.; San-Félix, A.; Balzarini, J.; De Clercq, E.; Camarasa, M. J. TSAO analogues. Stereospecific synthesis and anti-HIV-1 activity of 1-[2′,5′-bis-O-(tert-butyldimethylsilyl)- β-D-ribofuranosyl]-3′-spiro-5″-(4″-amino-1 ″,2″-oxathiole 2″,2″-dioxide) pyrimidine and pyrimidine-modified nucleosides. J. Med. Chem. 1992, 35, 2988-2995.
34. Velázquez, S.; San-Félix, A.; Pérez-Pérez, M. J.; Balzarini, J.; De Clercq, E.; Camarasa, M. J. TSAO analogues. 3. Synthesis and anti-HIV-1 activity of 2′,5′-bis-O-(tert-butyldimethylsilyl)- β-D-ribofuranosyl 3′-spiro-5″-(4″-amino-1″, 2″-oxathiole 2″,2″-dioxide) purine and purine-modified nucleosides. J. Med. Chem. 1993, 36, 3230-3239.
35. San-Félix, A.; Velázquez, S.; Pérez-Pérez, M. J.; Balzarini, J.; De Clercq, E.; Camarasa, M. J. Novel series of TSAO-T derivatives. Synthesis and anti-HIV-1 activity of 4-, 5-, and 6-substituted pyrimidine analogues. J. Med. Chem. 1994, 37, 453-460.
36. Alvarez, R.; Velázquez, S.; San-Félix, A.; Aquaro, S.; De Clercq, E.; Perno, C. F.; Karlsson, A.; Balzarini, J.; Camarasa, M. J. 1,2,3-Triazole-[2′,5′-bis-O-(tert-butyldimethylsilyl) -β-D-ribofuranosyl]-3′-spiro-5″-(4″-amino-1″, 2″-oxathiole 2″,2″-dioxide) (TSAO) analogues: synthesis and anti-HIV-1 activity. J. Med. Chem. 1994, 37, 4185-4194.
37. Velázquez, S.; Alvarez, R.; San-Félix, A.; Jimeno, M. L.; De Clercq, E.; Balzarini, J.; Camarasa, M. J. Synthesis and anti-HIV activity of [AZT]-[TSAO-T] and [AZT]-[HEPT] dimers as potential multifunctional inhibitors of HIV-1 reverse transcriptase. J. Med. Chem. 1995, 38, 1641-1649.
38. Ingate, S.; Pérez-Pérez, M. J.; De Clercq, E.; Balzarini, J.; Camarasa, M. J. Synthesis and anti-HIV-1 activity of novel TSAO-T derivatives modified at the 2′- and 5′-positions of the sugar moiety. Antiviral Res. 1995, 27, 281-299.
39. Velázquez, S.; Chamorro, C.; Pérez-Pérez, M. J.; Alvarez, R.; Jimeno, M. L.; Martin-Domenech, A.; Perez, C.; Gago, F.; De Clercq, E.; Balzarini, J.; San-Félix, A.; Camarasa, M. J. Abasic analogues of TSAO-T as the first sugar derivatives that specifically inhibit HIV-1 reverse transcriptase. J. Med. Chem. 1998, 41, 4636-4647.
40. Alvarez, R.; Jimeno, M. L.; Gago, F.; Balzarini, J.; Pérez- Pérez, M. J.; Camarasa, M. J. Novel 3′-spiro nucleoside analogues of TSAO-T. Part II. A comparative study based on NMR conformational analysis in solution and theoretical calculations. Antiviral Chem. Chemother. 1998, 9, 333-340.
41. Velázquez, S.; Tuñón, V.; Jimeno, M. L.; Chamorro, C.; De Clercq, E.; Balzarini, J.; Camarasa, M. J. Potential multifunctional inhibitors of HIV-1 reverse transcriptase. Novel [AZT]-[TSAO-T] and [d4T]-[TSAO-T] heterodimers modified in the linker and in the dideoxynucleoside region. J. Med. Chem. 1999, 42, 5188-5196.
42. Chamorro, C.; De Clercq, E.; Balzarini, J.; Camarasa, M. J.; San-Félix, A. TSAO-T analogues bearing amino acids at position N-3 of thymine: synthesis and anti-human immunodeficiency virus activity. Antiviral Chem. Chemother. 2000, 11, 61-69.
43. Chamorro, C.; Pérez-Pérez, M. J.; Rodríguez-Barrios, F.; Gago, F.; De Clercq, E.; Balzarini, J.; San-Félix, A.; Camarasa, M. J. Exploring the role of the 5′-position of TSAO-T. Synthesis and anti-HIV evaluation of novel TSAO-T derivatives. Antiviral Res. 2001, 50, 207-222.
44. Lobatón, E.; Rodríguez-Barrios, F.; Gago, F.; Pérez-Pérez, M. J.; De Clercq, E.; Balzarini, J.; Camarasa, M. J.; Velázquez, S. Synthesis of 3″-substituted TSAO derivatives with anti-HIV-1 and anti-HIV-2 activity through an efficient palladium-catalyzed cross-coupling approach. J. Med. Chem. 2002, 45, 3934-3945.
45. Bonache, M. C.; Chamorro, C.; Cordeiro, A.; Camarasa, M. J.; Jimeno, M. L.; San-Félix, A. Synthesis of novel bi-, tri-, and tetracyclic nucleosides by reaction of a common cyclic enamine derived from TSAO-T with nucleophiles. J. Org. Chem. 2004, 69, 8758-8766.
46. de Castro, S.; Lobatón, E.; Pérez-Pérez, M. J.; San-Félix, A.; Cordeiro, A.; Andrei, G.; Snoeck, R.; De Clercq, E.; Balzarini, J.; Camarasa, M. J.; Velázquez, S. Novel [2′,5′- bis-O-(tert-butyldimethylsilyl)-β-D-ribofuranosyl]-3′-spiro-5″- (4″-amino-1″,2″-oxathiole-2″,2″-dioxide) derivatives with anti-HIV-1 and anti-human-cytomegalovirus activity. J. Med. Chem. 2005, 48, 1158-1168.
47. de Castro, S.; Lozano, A.; Jimeno, M. L.; Pérez-Pérez, M. J.; San-Félix, A.; Camarasa, M. J.; Velázquez, S. Unprecedented lability of the 5′-O-tert-Butyldimethylsilyl group from 3′-spiro-5″-(4″-acylamino-1″,2″-oxathiole- 2″,2″-dioxide) nucleoside derivatives via neighboring group participation of the 4″-acylamino residue. J. Org. Chem. 2006, 71, 1407-1415.
48. Shi, C.; Mellors, J. W. A recombinant retroviral system for rapid in vivo analysis of human immunodeficiency virus type 1 susceptibility to reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 1997, 41, 2781-2785.
49. Sluis-Cremer, N.; Temiz, N. A.; Bahar, I. Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding. Curr. HIV Res. 2004, 2, 323-332.
50. Srivastava, S.; Sluis-Cremer, N.; Tachedjian, G. Dimerization of human immunodeficiency virus type 1 reverse transcriptase as an antiviral target. Curr. Pharm. Des. 2006, 12, 1879-1894.